BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals’ management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.
Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 (international) with the conference code 13732796. The live webcast and replay of the conference call can be accessed under “News & Events” in the Investor Relations section of the Company’s website, www.scpharmaceuticals.com.
About scPharmaceuticals
scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead programs focus on the subcutaneous, self-administration of IV-strength treatments in heart failure and infectious disease. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Taudvin
scPharmaceuticals Inc., 781-301-6706
[email protected]
Investors:
Hans Vitzthum
LifeSci Advisors, 617-430-7578
[email protected]
- Electric Boats Market to Reach USD 15.1 Billion by 2033 | Key Players: ABB, Siemens, Kongsberg | Future Market Insights, Inc. - October 6, 2024
- ROSEN, GLOBAL INVESTOR COUNSEL, Encourages WEBTOON Entertainment Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBTN - October 6, 2024
- ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE - October 6, 2024
